Promising combo for bile duct cancer trial halted early

NCT ID NCT04203160

First seen Jan 04, 2026 · Last updated May 13, 2026 · Updated 17 times

Summary

This study tested whether adding the experimental drug CPI-613 to standard chemotherapy (gemcitabine and cisplatin) could help people with advanced biliary tract cancer that cannot be removed by surgery. About 75 participants were planned, but the trial was stopped early. The goal was to find the best dose and see if the combination improved tumor shrinkage compared to chemo alone.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BILIARY TRACT CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Allegheny Health Network

    Pittsburgh, Pennsylvania, 15224, United States

  • Atlantic Health System

    Morristown, New Jersey, 07960, United States

  • Fred Hutch/University of Washington Cancer Consortium

    Seattle, Washington, 98109, United States

  • Northwestern University -- Lurie Comprehensive Cancer Center

    Chicago, Illinois, 60611, United States

  • University Hospitals - Seidman Cancer Center

    Cleveland, Ohio, 44106, United States

  • University of Arizona Cancer Center

    Tucson, Arizona, 85724, United States

  • University of Michigan Rogel Cancer Center

    Ann Arbor, Michigan, 48109, United States

  • University of Texas Southwestern -- Simmons Comprehensive Cancer Center

    Dallas, Texas, 75390, United States

  • University of Wisconsin - Carbone Cancer Center

    Madison, Wisconsin, 53705, United States

  • Vanderbilt-Ingram Cancer Center

    Nashville, Tennessee, 37232, United States

Conditions

Explore the condition pages connected to this study.